LIFE RSI Chart
Last 7 days
18.3%
Last 30 days
25.8%
Last 90 days
-1.0%
Trailing 12 Months
-17.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 7.0M | 0 | 3.7M | 353.0K |
2022 | 10.4M | 10.4M | 10.4M | 10.4M |
2021 | 0 | 0 | 0 | 10.4M |
2020 | 2.9M | 5.4M | 7.9M | 10.5M |
2019 | 0 | 0 | 0 | 422.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 06, 2024 | broadfoot jill marie | sold | -2,687 | 1.69 | -1,590 | chief financial officer |
Feb 05, 2024 | broadfoot jill marie | acquired | - | - | 3,750 | chief financial officer |
Feb 05, 2024 | shukla sanjay | acquired | - | - | 10,375 | president and ceo |
Feb 05, 2024 | denyes nancy | acquired | - | - | 2,688 | general counsel |
Dec 12, 2023 | shukla sanjay | bought | 14,136 | 1.178 | 12,000 | president and ceo |
Dec 11, 2023 | shukla sanjay | bought | 3,510 | 1.17 | 3,000 | president and ceo |
Nov 13, 2023 | shukla sanjay | bought | 15,085 | 1.111 | 13,578 | president and ceo |
Nov 10, 2023 | shukla sanjay | bought | 1,618 | 1.138 | 1,422 | president and ceo |
Jul 28, 2023 | shukla sanjay | bought | 30,223 | 2.0149 | 15,000 | president and ceo |
May 17, 2023 | coughlin timothy | gifted | - | - | -6,000 | - |
Which funds bought or sold LIFE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 121,173 | 121,173 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 309,307 | 309,307 | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | unchanged | - | 254,412 | 918,711 | 0.10% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -61.99 | -17,747 | 19,672 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -83.00 | -98,000 | 30,000 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 51.31 | 221,170 | 423,604 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 8.54 | 1,238,950 | 3,711,520 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 90,077 | 325,276 | -% |
May 15, 2024 | MORGAN STANLEY | added | 23.83 | 15,999 | 38,450 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 4.99 | 94,791 | 304,541 | -% |
Unveiling aTyr Pharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to aTyr Pharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
aTyr Pharma Inc News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Revenue | - | 235,000 | - | 353,000 | 595,857 | 838,714 | 1,081,571 | 1,324,429 | 1,567,286 | 1,810,143 | 2,053,000 | 148,000 | 189,000 | 8,065,000 | 4,124,500 | 184,000 | 94,000 |
Operating Expenses | 5.7% | 16,871,000 | 15,959,000 | 12,968,000 | 12,787,000 | 18,336,000 | 13,492,000 | 12,584,000 | 12,378,000 | 8,640,000 | 6,993,000 | 6,660,000 | 6,507,000 | 6,206,000 | 6,106,000 | 5,682,000 | 5,735,000 |
S&GA Expenses | -100.0% | - | 3,204,000 | 2,649,000 | 3,408,000 | 3,426,000 | 3,625,000 | 3,449,000 | 3,482,000 | 2,685,000 | 2,295,000 | 2,044,000 | 2,146,000 | 2,590,000 | 2,516,000 | 1,883,000 | 2,421,000 |
R&D Expenses | 4.8% | 13,364,000 | 12,755,000 | 10,319,000 | 9,379,000 | 14,910,000 | 9,867,000 | 9,135,000 | 8,896,000 | 5,955,000 | 4,698,000 | 4,616,000 | 4,361,000 | 3,616,000 | 3,590,000 | 3,799,000 | 3,314,000 |
EBITDA Margin | 0.2% | -140 | -140 | -12.10 | -6.40 | -4.34 | -3.22 | -3.20 | -3.19 | -3.19 | - | - | - | - | - | - | - |
Interest Expenses | -2.6% | 38,000 | 39,000 | 39,000 | 46,000 | 54,000 | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | 0% | -142 | -142 | -12.26 | -6.44 | -4.37 | -3.25 | -3.24 | -3.24 | -3.23 | - | - | - | - | - | - | - |
Net Income | -4.8% | -15,500,000 | -14,792,000 | -11,300,000 | -11,952,000 | -7,520,000 | -13,244,000 | -12,421,000 | -12,154,000 | -8,556,500 | -4,931,000 | -6,599,000 | -6,447,000 | 1,752,000 | -5,973,000 | -5,645,000 | -5,848,000 |
Net Income Margin | -7.0% | -152 | -142 | -11.66 | -6.41 | -4.37 | -4.46 | -3.92 | -3.72 | -3.23 | - | - | - | - | - | - | - |
Free Cashflow | -102.2% | -22,397,000 | -11,079,000 | -10,116,000 | -1,836,000 | -11,488,000 | -12,707,000 | -9,170,000 | -10,162,000 | -8,104,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -6.1% | 113 | 121 | 125 | 133 | 137 | 96.00 | 96.00 | 96.00 | 105 | 116 | 124 | 49.00 | 55.00 | 39.00 | 42.00 | 48.00 | 54.00 | 36.00 | 44.00 | 49.00 | 50.00 |
Current Assets | -5.9% | 97.00 | 103 | 107 | 114 | 119 | 81.00 | 85.00 | 93.00 | 103 | 114 | 122 | 46.00 | 52.00 | 36.00 | 38.00 | 44.00 | 50.00 | 32.00 | 39.00 | 44.00 | 45.00 |
Cash Equivalents | -69.8% | 7.00 | 23.00 | 10.00 | 12.00 | 21.00 | 10.00 | 18.00 | 8.00 | 8.00 | 2.00 | 60.00 | 2.00 | 13.00 | 17.00 | 18.00 | 22.00 | 39.00 | 9.00 | 17.00 | 15.00 | 13.00 |
Net PPE | -3.2% | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 3.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 |
Current Liabilities | -2.7% | 16.00 | 16.00 | 13.00 | 12.00 | 14.00 | 14.00 | 11.00 | 9.00 | 6.00 | 6.00 | 6.00 | 7.00 | 4.00 | 6.00 | 8.00 | 10.00 | 10.00 | 13.00 | 12.00 | 11.00 | 11.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 | 5.00 | 6.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 | 5.00 | 7.00 | 9.00 | 8.00 | 8.00 | 8.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 | 5.00 | 6.00 |
Shareholder's Equity | -7.0% | 84.00 | 91.00 | 98.00 | 106 | 110 | 71.00 | 77.00 | 86.00 | 98.00 | 109 | 117 | 41.00 | 50.00 | 31.00 | 32.00 | 36.00 | 42.00 | 21.00 | 27.00 | 30.00 | 29.00 |
Retained Earnings | -3.3% | -483 | -468 | -453 | -441 | -429 | -417 | -410 | -396 | -384 | -372 | -363 | -356 | -345 | -338 | -333 | -327 | -320 | -322 | -316 | -310 | -304 |
Additional Paid-In Capital | 1.7% | 568 | 559 | 552 | 548 | 540 | 490 | 488 | 484 | 484 | 482 | 481 | 397 | 395 | 370 | 366 | 363 | 363 | 344 | 343 | 341 | 334 |
Shares Outstanding | 8.0% | 68.00 | 63.00 | 59.00 | 57.00 | 53.00 | 29.00 | 29.00 | 28.00 | 28.00 | 19.00 | 18.00 | 15.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 2.1% | -0.18 | -0.19 | -0.19 | -0.18 | -0.18 | -0.18 | -0.18 | -0.18 | -0.18 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.16 | -0.16 | -0.16 | -0.16 | - | - | - |
Float | - | - | - | - | 121 | - | - | - | 77.00 | - | - | - | 76.00 | - | - | - | 25.00 | - | - | - | 10.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -102.3% | -22,380 | -11,062 | -9,559 | -12,010 | -590 | -10,369 | -12,281 | -9,117 | -10,119 | -8,086 | -11,470 | -7,692 | -5,827 | -5,401 | -5,555 | -6,403 | 2,058 | -4,916 | -4,253 | -4,821 | -6,023 |
Share Based Compensation | -100.0% | - | 659 | 664 | 658 | 619 | 605 | 615 | 517 | 417 | 414 | 442 | 398 | 360 | 340 | 324 | 378 | 423 | 425 | 278 | 509 | 571 |
Cashflow From Investing | -107.6% | -1,356 | 17,818 | 4,383 | -4,156 | -38,172 | 1,999 | 20,649 | 9,971 | 14,626 | -49,348 | -14,849 | -3,974 | -23,395 | 3,203 | 1,740 | -9,449 | 11,406 | -1,220 | 7,209 | 2,291 | -3,355 |
Cashflow From Financing | 28.1% | 7,730 | 6,034 | 2,682 | 8,018 | 49,496 | 918 | 3,013 | 39.00 | 1,481 | 28.00 | 83,869 | 1,271 | 24,857 | 999 | 334 | -1,969 | 16,779 | -1,995 | -122 | 4,072 | -619 |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 235 | $ 0 |
Revenue, Product and Service [Extensible Enumeration] | License and Collaboration Revenues [Member] | License and Collaboration Revenues [Member] |
Operating expenses: | ||
Research and development | $ 13,364 | $ 9,379 |
General and administrative | 3,507 | 3,408 |
Total operating expenses | 16,871 | 12,787 |
Loss from operations | (16,636) | (12,787) |
Total other income (expense), net | 1,149 | 835 |
Consolidated net loss | (15,487) | (11,952) |
Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited | (4) | 1 |
Net loss attributable to aTyr Pharma, Inc. | $ (15,491) | $ (11,951) |
Net loss per share - basic | $ (0.23) | $ (0.29) |
Net loss per share - diluted | $ (0.23) | $ (0.29) |
Shares used in computing net loss per share, basic | 66,080,593 | 41,897,706 |
Shares used in computing net loss per share, diluted | 66,080,593 | 41,897,706 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,808 | $ 22,544 |
Available-for-sale investments | 77,688 | 75,622 |
Other receivables | 2,476 | 2,436 |
Prepaid expenses | 9,944 | 2,390 |
Total current assets | 96,916 | 102,992 |
Restricted cash | 3,214 | 3,484 |
Property and equipment, net | 5,353 | 5,531 |
Operating lease, right-of-use assets | 5,999 | 6,727 |
Financing lease, right-of-use assets | 1,639 | 1,788 |
Other assets | 130 | 131 |
Total assets | 113,251 | 120,653 |
Current liabilities: | ||
Accounts payable | 4,893 | 3,529 |
Accrued expenses | 9,950 | 11,559 |
Current portion of operating lease liability | 629 | 831 |
Current portion of financing lease liability | 507 | 497 |
Total current liabilities | 15,979 | 16,416 |
Long-term operating lease liability, net of current portion | 11,693 | 12,339 |
Long-term financing lease liability, net of current portion | 1,297 | 1,428 |
Commitments and contingencies (Note 4) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; no shares issued or outstanding as of March 31, 2024 (unaudited) and December 31, 2023 | ||
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; issued and outstanding shares - 68,354,033 as of March 31, 2024 (unaudited) and 63,286,404 as of December 31, 2023 | 68 | 63 |
Additional paid-in capital | 568,070 | 558,692 |
Accumulated other comprehensive loss | (158) | (74) |
Accumulated deficit | (483,514) | (468,023) |
Total aTyr Pharma stockholders’ equity | 84,466 | 90,658 |
Noncontrolling interest in Pangu BioPharma Limited | (184) | (188) |
Total stockholders' equity | 84,282 | 90,470 |
Total liabilities and stockholders’ equity | $ 113,251 | $ 120,653 |